Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830

This article was originally published here

Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis. Enrollment in a large randomized

The post Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply